ridethepig | A retrace in play for home fitness📌 Peloton
One of the aspects of consumer behaviour that has changed the most over the past few months has been the approach to fitness and home-enablers. As we introduced a deep and accurate buy approach it helped that Fed and other CB's helped to raise the bar even higher with their ambitious and methodical (right...) approaches.
So, as with many other improvements, the $2,000 coat hanger consists of a monthly subscription service which members can go through daily. However we would need to see consumers continue to cough up $2,000 for an exercise bike when the economy is tanking. We are certainly not ready for mass adoption and growth until the economy heals. Armed with a pair of trainers and one can produce the same outcome although I refuse to demonstrate illustratively ... maybe one day on Tradingview streams!
In any case, the format of the flow is quite simple. Throughout the impulsive leg it was a matter of letting bulls over-extend before finding a comprehensive fade.
As usual thanks for keeping the feedback coming 👍 or 👎
Homeenablers
ridethepig | Bullish On Home Fitness ... Pelaton At The Lows!We can start to look for single stock opportunities as behavioural economics changes as a result of the Coronavirus impact. We are talking about a dramatic loss in confidence, global OCD patient numbers are ticking higher which btw itself from time-to-time be a very useful indicator.
We are talking about an outbreak which has triggered volatility across the board and home enablers will benefit. Would it not be opportune to direct our focus towards a new sector? How to do that will be seen in the following months in the stages of transfer.
As the main background to the theme, VIX now reaches the final stages in the move towards 85 it's time to start looking for value areas in PTON:
We are starting to reach the initial targets in SPX and DAX selloffs which implies there will be some profit taking from sellers despite the fact we are entering into a recession:
DAX
SPX
Other opps... GILD will continue doing the heavy lifting on Remdesivir (GS-5734) side, this is their free pass into the Chinese Healthcare system. Models will need to start quickly repricing revenue from the Hep B cases in China. GILD will do the heavy lifting here, +/- $20 upside available on the headline for FDA approval which looks around the corner. Flow-wise, the initial target area from the latest technical break comes into play at 86. xx (+25% from current levels).
Highlights on the ownership front going to usual suspects in here, Morgan Stanley, Soros, Blackrock, Eminence and Fidelity. This is another known position, it's going to be decided in the next few days. Thanks as usual for keeping the likes and comments rolling.